

TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Leuven (Belgium) – November 29, 2013 – TiGenix NV (Euronext Brussels: TIG) publishes today transparency notifications pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

It concerns the following notifications:

1. Notification by the related companies Grifols S.A. / Gri-Cel S.A. (both with address at Avenida de la Generalitat 152, 08174 Sant Cugat del Vallès, Barcelona, Spain), regarding the crossing above the 20% threshold on November 22, 2013 following the acquisition of shares by Gri-Cel S.A., after which the participations of these companies were as follows (compared to the denominator of 160,476,620 shares):
 - Grifols S.A.: 0 shares (0%),
 - Gri-Cel S.A.: 34,188,034 shares (21.30%),
 - Total: 34,188,034 shares (21.30%).

The chain of controlled undertakings through which the holdings are effectively held, is as follows: Grifols, S.A. controls Instituto Grifols, S.A. and Instituto Grifols, S.A. controls Gri-Cel, S.A.

2. Notification by the company Ysios Capital Partners S.G.E.C.R. (with address at Av Diagonal 600, entl 2a, 08021 Barcelona, Spain), who notifies alone, following the passive crossing below the lowest threshold of 3% on November 22, 2013 (compared to the denominator of 160,476,620 shares).

Ysios Capital Partners S.G.E.C.R. is the management company of Ysios Biofund I FCR (a collective investment undertaking within the meaning of Article 9, §2 of the Royal Decree of February 14, 2008) and exercises the voting rights attached to the shares owned by this fund at its own discretion.

Ysios Capital Partners S.G.E.C.R. is not controlled.

For further details regarding these notifications, we refer to our website: <http://www.tigenix.com/en/page/26/shareholders>.

For more information:

Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com

Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com

TiGenix

Hans Herklots
hans.herklots@tigenix.com
+32 16 39 60 97

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.